Short answer:
In theory, a generic version of Lumigan (brimonidine tartrate) can be sold as soon as the last of its patents expire and a generic manufacturer gets approval from the relevant drug‑regulatory authority. In practice, the actual appearance of a generic in the market can take a few more months to a few years after the patents are gone, because the company still needs to file for approval, go through the FDA (or EMA, PMDA, etc.) review process, and set up manufacturing and distribution.
---
Why the “after‑expiration” window isn’t immediate
| Step | What happens | Typical time‑frame |
|------|--------------|--------------------|
| Patents expire | The legal protection that prevented other companies from making the drug ends. | 2023–2028 for different patents on brimonidine (exact dates vary by jurisdiction). |
| Generic manufacturer files an application | A company that wants to sell a generic must submit an Investigational New Drug (IND) or a New Drug Application (NDA) with the FDA, or an equivalent dossier to the EMA, PMDA, etc. | 1–3 months for filing. |
| Regulatory review | The authority evaluates bioequivalence, safety data, labeling, etc. | 6–12 months (often longer for ophthalmic products). |
| Approval granted | The generic can be marketed. | 1–3 months after regulatory decision. |
| Market entry | The generic is produced, priced, and made available to prescribers and patients. | 1–3 months after approval. |
So, while the “patent cliff” is a signal that the market will open up, the practical launch of a generic can lag by 1–3 years after the patents actually expire.
---
Current status (as of 2026)
| Market | Status | Notes |
|--------|--------|-------|
| United States | No FDA‑approved generic brimonidine eye drops yet | The last U.S. patents on the ophthalmic formulation are set to expire in 2025 (or 2026, depending on the specific claim). The FDA has not yet approved any generic. |
| European Union | Pending | Several generic manufacturers have submitted applications to the EMA; approval may come in late 2026–2027. |
| Canada | Pending | Health Canada has received generic submissions, but the review process is still underway. |
| Australia | Pending | Australian Therapeutic Goods Administration (TGA) has been reviewing generic applications, with possible approval by mid‑2027. |
| Other markets | Variable | Some countries (e.g., India, Brazil) may have already approved generic brimonidine, but these generics may differ in formulation or strength. |
If you are in the U.S. or EU and you’re waiting for a cheaper version, keep an eye on the FDA’s “Generic Drug User Fee” (GDUFA) and EMA’s “Generic Medicine” portal. The FDA usually publishes a “Generic Drug Approvals” list each month; you can find the exact approval date there once the generic is cleared.
---
What to do right now
1. Check the patent status in your country.
- In the U.S., you can search the USPTO database for “brimonidine tartrate ophthalmic” to see the latest expiration dates.
- In the EU, the European Patent Register (EPO) lists the relevant patents.
2. Monitor regulatory approvals.
- The FDA’s website (or your local regulatory body) publishes a list of approved generic ophthalmic drugs.
- The EMA’s “European Generic Medicines Register” shows pending approvals.
3. Talk to your ophthalmologist or pharmacist.
- They’ll know if any generic competitors have already entered the market or are in the pipeline.
- They can advise if a generic combination product (brimonidine + timolol, for example) is available.
4. Ask your insurer.
- Some insurance plans automatically switch patients to generics once they’re available, often at a lower copay.
---
Bottom line
Yes – a generic version of Lumigan will likely become available after the last relevant patent expires. However, the actual launch can be delayed by a year or more, depending on how quickly a generic manufacturer files and passes regulatory review. Keep an eye on FDA/EMA updates and discuss options with your eye care provider if you’re hoping to switch to a generic in the near future.